Please assess the completion status of the following clinical trial:

Trial Title: A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females age 25-65 with SCID (DSM-IV) diagnosis of alcohol dependence who~2. Want to stop or decrease their drinking~3. Are not participating in any formal treatment for alcohol dependence (12-step meetings are not considered treatment)~4. Are able to provide voluntary informed consent~5. Have at least 4 heavy drinking days in the past 30 days~6. If female of childbearing potential, are willing to use approved form of contraception from screening until after the psilocybin administration sessions~7. Have a family member or friend who can pick them up and stay with them overnight after the psilocybin administration sessions~8. Are able to provide adequate locator information.~Exclusion Criteria:~1. Medical conditions that would preclude safe participation in the trial (e.g., seizure disorder, significantly impaired liver function, coronary artery disease, heart failure, uncontrolled hypertension (above 165/95 mmHg at screening), history of cerebrovascular accident, asthma, hyperthyroidism, narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, or bladder-neck obstruction)~2. Exclusionary psychiatric conditions (schizophrenia, schizoaffective disorder, bipolar disorder, current major depressive episode, current post-traumatic stress disorder, current suicidality or history of medically serious suicide attempt)~3. Cognitive impairment (Folstein Mini Mental State Exam score \< 26)~4. A family history of schizophrenia or schizoaffective disorder (first or second degree relatives), or bipolar disorder type 1 (first degree relatives)~5. History of hallucinogen use disorder, or any use in the past 1 year, or \>25 lifetime uses;~6. Cocaine, psychostimulant, opioid, or cannabis dependence (past 12 months)~7. Current non-medical use of cocaine, psychostimulants, or opioids (past 30 days)~8. Significant alcohol withdrawal (CIWA-Ar score greater than 7. Patients presenting at screening in withdrawal may be referred for detoxification and reassessed within 30 days)~9. Serious ECG abnormalities (e.g., evidence of ischemia, myocardial infarction, QTc prolongation \[QTc \> .045 for men, QTc \> .047 for women\])~10. Serious abnormalities of complete blood count or chemistries~11. Active legal problems with the potential to result in incarceration~12. Pregnancy or lactation~13. Need to take medication with significant potential to interact with study medications (e.g., antidepressants, antipsychotics, psychostimulants, treatments for addictions, other dopaminergic or serotonergic agents, lithium, anticonvulsants).~14. Allergy or hypersensitivity to psilocybin or diphenhydramine.~15. High risk of adverse emotional or behavioral reaction based on investigator's clinical evaluation (e.g., evidence of serious personality disorder, antisocial behavior, serious current stressors, lack of meaningful social support).

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Psilocybin (Type: EXPERIMENTAL): Psilocybin 25 mg/70 kg PO administered at week 4, 25-40 mg/70 kg PO administered at week 8.
- Diphenhydramine (Type: ACTIVE_COMPARATOR): Diphenhydramine 50 mg PO administered at week 4, 50-100 mg PO administered at week 8.

Based on this trial design, predict the completion outcome and termination type (if applicable).